Abstracts tagged "race/ethnicity"

Abstract Number: 1203 • ACR Convergence 2022
The Association Between Anti-Citrullinated Peptide Antibodies and Subclinical Interstitial Lung Disease in Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis
Jenna Lanz¹, Jan Hughes-Austin², Anna Podolanczuk³, John Kim⁴, John Austin⁵, William Robinson⁶, Ganesh Raghu⁷, Eric Hoffman⁸, John Newell Jr⁸, Jubal Watts Jr⁹, P. Hrudaya Nath⁹, Sushilkumar Sonavane¹⁰, R. Graham Barr⁵ and Elana Bernstein¹, ¹Columbia University, New York, NY, ²University of California, San Diego, San Diego, CA, ³Weill Cornell Medical College, New York, NY, ⁴University of Virginia School of Medicine, Charlottesville, VA, ⁵Columbia University Medical Center, New York, NY, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷University of Washington, Seattle, WA, ⁸University of Iowa, Iowa City, IA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Mayo Clinic, Rochester, MN
Background/Purpose: We previously demonstrated a significant association between serum anti-CCP levels and prevalence of interstitial lung abnormalities (ILA) in community-dwelling adults. A greater number of…
Abstract Number: 0131 • ACR Convergence 2022
Racial Differences in Bone Health of Sarcoidosis Patients: A Retrospective Study
Emily Peninger¹, Christian Ascoli², Rachel Lane², Subash Kukreja², Robert Baughman³ and Nadera Sweiss², ¹University of Chicago, Chicago, IL, ²University of Illinois at Chicago, Chicago, IL, ³University of Cincinnati, Cincinnati, OH
Background/Purpose: Bone health in sarcoidosis is a complex topic, though data regarding racial differences in this population is lacking. Our study sought to identify racial…
Abstract Number: 1378 • ACR Convergence 2022
Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort
Ha-Seul Jeoung¹, Kuan Liu¹, Roberta Berard², Wes Fidler³, Janet Pope⁴, Johannes Roth⁵, Carter Thorne⁶, Earl Silverman⁷ and Deborah Levy⁸, ¹University of Toronto, Toronto, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³St. Joseph's Hospital, Thunder Bay, ON, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Ottawa, Ottawa, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: The long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care is not well documented. The present study aims to fill…
Abstract Number: 0211 • ACR Convergence 2022
Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus
Sophia Lutgen¹, S. Sam Lim², Laura D. Aspey², Gaobin Bao³, Charmayne Dunlop-Thomas², Jessica N. Williams² and Cristina Drenkard², ¹Mount Sinai Morningside-West, New York, NY, ²Emory University, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Due to demographic and disease-related factors, patients with lupus are deemed to be more vulnerable to COVID-19 infection than the general population, but they…
Abstract Number: 1383 • ACR Convergence 2022
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Rebecca Olveda, Jessica Neely and Susan Kim, UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…
Abstract Number: 0286 • ACR Convergence 2022
Efficacy and Safety of Upadacitinib in Patients Across Races with Rheumatoid Arthritis: A Post Hoc Analysis of Six Phase 3 Clinical Trials
Grace Wright¹, Eduardo Mysler², Iris Navarro-Millan³, Yoshiya Tanaka⁴, Samuel Anyanwu⁵, Jianzhong Liu⁵, Oishi Tanjinatus⁵, Andrew Garrison⁵ and Alvin Wells⁶, ¹Association of Women in Rheumatology, New York, NY, ²Department of Rheumatology, OMI (Medical Research Organization), Buenos Aires, Argentina, ³Weill Cornell Medicine, New York, NY, ⁴University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁵AbbVie, Inc., North Chicago, IL, ⁶Aurora Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: RA affects diverse patient populations with varying disease severity and treatment responses. However, data on treatment response to advanced therapies by race are limited.1…
Abstract Number: 1583 • ACR Convergence 2022
Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Lindsay Helget¹, James O'Dell¹, Jeff Newcomb¹, Maria Androsenko², Mary Brophy², Anne Davis-Karim³, Bryant England¹, Ryan Ferguson², Michael Pillinger⁴, Tuhina Neogi⁵, Paul Palevsky⁶, Hongsheng Wu² and Ted Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ³VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR recommends a treat-to-target strategy in the management of gout, involving titration of urate lowering therapy (ULT) to a serum urate (SU) goal…
Abstract Number: 0449 • ACR Convergence 2022
Higher Disease Acuity at Presentation and Increased Lower Respiratory Involvement in Hispanic and Black Patients with ANCA-Associated Vasculitis
Mark Riley¹, Wenlu Xiong¹ and Najia Shakoor², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Hinsdale, IL
Background/Purpose: ANCA-associated vasculitis (AAV) is a systemic small-vessel vasculitis comprising granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and renal-limited vasculitis…
Abstract Number: 1753 • ACR Convergence 2022
Temporal Trends of SLE Mortality Among Various Ethnic Categories Across the United States: 2001-to 2020 Analysis from WONDER Database
Ikwinder Preet Kaur¹, Harjot Jagdey², hasan Mirza³, Waqar Mughal⁴ and Pankaj Bansal⁵, ¹Rutgers/Monmouth Medical Center, Long branch, NJ, ²BronxCare Hospital, Bronx, NY, ³Berkshire Medical Center, Pittsfield, MA, ⁴DHQ teaching hospital, Gujrat, Pakistan, ⁵Mayo Clinic, Eau Claire, WI
Background/Purpose: Racial disparities in SLE have been well described. Blacks are disproportionately affected, and have a higher incidence, disease severity, and mortality compared to Whites,…
Abstract Number: 0089 • ACR Convergence 2022
Racial Disparities in Rheumatology Clinical Trials
Pushti Khandwala¹, Anila Hussain² and Irene Tan³, ¹Einstein Medical Center Philadelphia, Glen Mills, PA, ²Crozer Chester Medical Center, Glen Mills, PA, ³Einstein Medical Center Philadelphia, Philadelphia, PA
Background/Purpose: Healthcare disparities exist in patients living with rheumatologic diseases. Factors contributing to disparities include age, sex, race, or sociodemographic variables, each playing a crucial…
Abstract Number: 0488 • ACR Convergence 2022
Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center
Raj Vachhani¹, Peng Li², Mehdi Tavakoli², Lanning Kline² and Angelo Gaffo², ¹University of Alabama at Birmingham, Homewood, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: A prior study evaluated incidence rates of biopsy proven giant cell arteritis (GCA) among black and white patients, concluding that GCA occurs at a…
Abstract Number: 1766 • ACR Convergence 2022
COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
Angie El-Said¹, Areeb Ahmad², Massimo Valenti³, Neel K. Shah¹, Susana Soto¹ and Shazia Beg⁴, ¹University of Central Florida College of Medicine, Orlando, FL, ²University of Central Florida, Orlando, FL, ³Sapienza University of Rome, School of Medicine, Rome, Italy, ⁴UCF, Orlando, FL
Background/Purpose: Although various systemic and dermatologic manifestations associated with COVID-19 have been reported in the literature, investigations of how these manifestations vary by race remain…
Abstract Number: 0090 • ACR Convergence 2022
Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis
Niti Goel, TrialSpark, Duke University, Durham, NC
Background/Purpose: Participant diversity in clinical trials of therapeutics in rheumatology is important to evaluate to better understand how individuals of different races and ethnicities might…
Abstract Number: 0521 • ACR Convergence 2022
Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis
Lauren Smith¹, Jamie Perin², Adrianne Woods², Fredrick Wigley³, Laura Hummers⁴ and Ami Shah⁵, ¹Johns Hopkins, District Heights, MD, ²John Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins Univerisity, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Black patients with systemic sclerosis (SSc) develop SSc at a younger age and have more severe disease than White patients, including a higher prevalence…
Abstract Number: 1793 • ACR Convergence 2022
Prevalence of HLA B*5801 Allele Among African American Patients with Gout in an Academic Health Center
Namitha Nair, Dipanjan Debnath and FLORINA CONSTANTINESCU, MedStar Washington Hospital Center, Washington, DC
Background/Purpose: The presence of the HLA-B*5801 allele is strongly associated with Allopurinol Hypersensitivity Syndrome (AHS) manifesting as severe cutaneous adverse reactions (SCARs) like Drug rash…

« Previous Page
1
…
6
7
8
9
10
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].